Markers of inflammation and cardiovascular disease: Clinical applications of C-reactive protein determination

American Journal of Cardiovascular Drugs

Volumn 9, Issue SUPPL 1, 2009, Pages 3-7

  Martínez, Vicente Bertomeu ^a   González Juanatey, J Ramón ^b  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN;

BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONFERENCE PAPER; DIABETIC PATIENT; HEART INFARCTION; HUMAN; INFLAMMATION; PLEIOTROPY; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE; UNSTABLE ANGINA PECTORIS; BLOOD; REVIEW;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; INFLAMMATION;

EID: 77951246960     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/1153161-S0-000000000-00000     Document Type: Conference Paper

References (23)

1. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 864-8.
2. Roselló -Leti E, Rivera M, Martínez-Dolz L, et al. Inflammatory activation and left ventricular mass in essential hypertension. Am J Hypertens 2009; 22: 444-50.
3. Burke AP, Russel PT, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002; 105: 2019-23.
4. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
5. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
6. Ridker PM, Wilson P, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-25.
7. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008; 118: 2243-51.
8. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA 2007; 297: 611-9.
9. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-16.
10. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008; 121: S21-S31.
11. González-Gay MA, González-Juanatey C, Martín J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17.
12. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-8.
13. Kuch B, von Scheidt W, Kling B, et al. Differential impact of admission C-reactive protein levels on 28-day mortality risk in patients with ST-elevation versus non-ST-elevation myocardial infarction (from the Monitoring Trends and Determinants on Cardiovascular Diseases [MONICA]/Cooperative Health Research in the Region of Augsburg [KORA] Augsburg Myocardial Infarction Registry. Am J Cardiol 2008; 102: 1125-30.
14. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999; 319: 1492-5.
15. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
16. Pearson TA, Mensah GA, Alexander W, et al. Markers of inflammation and cardiovascular disease. Application to Clinical and Public Health Practice: a statement for Healthcare professionals from the centers for disease control and prevention and the American Heart Association.Circulation 2003; 107: 499-511.
17. Libby P, Ridker PM. Novel inflammation markers of coronary risk: theory vs practice. Circulation 1999; 100: 1148-50.
18. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-65.
19. Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46: 1855-62.
20. O'Keefe JH, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dL lower: lower is better and physiologically normal. Am J Col Cardiol 2004; 43: 2142-6.
21. Taglieri N, Fernandez-Berges DJ, Koenig W, et al; for the SIESTA Investigators. Plasma cystanin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Artherosclerosis 2009 Sep 20 [E-pub ahead of print].
22. Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359: 1897-908.
23. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-9.